16:47 , Jun 8, 2018 |  BC Week In Review  |  Company News

Cstone gets Chinese rights to Blueprint clinical pipeline

Blueprint Medicines Corp. (NASDAQ:BPMC) granted CStone Pharmaceuticals Co. Ltd. (Suzhou, China) exclusive rights to all three of Blueprint's clinical candidates in a deal potentially worth more than $386 million. CStone gained exclusive rights to develop and...
22:12 , Jun 4, 2018 |  BC Extra  |  Company News

CStone gains China rights to Blueprint programs

Blueprint Medicines Corp. (NASDAQ:BPMC) granted CStone Pharmaceuticals Co. Ltd. (Suzhou, China) exclusive rights to all three of Blueprint's clinical candidates in a deal potentially worth more than $386 million. CStone gained exclusive rights to develop...
22:54 , Jun 1, 2017 |  BC Extra  |  Financial News

Deciphera raises $52M in series C

Deciphera Pharmaceuticals LLC (Waltham, Mass.) raised $52 million in a series C round led by Viking Global Investors, Redmile Group and Sphera Global Healthcare Fund. Existing investor New Leaf Venture Partners also participated. Using its platform,...
01:05 , Apr 21, 2017 |  BC Innovations  |  Product R&D

Making marks at AACR

Biomarkers that could stratify patients, point to treatment combinations or predict toxicity were a major part of the conversation at this year’s AACR conference, where they emerged as potential difference makers for a range of...
00:30 , Dec 2, 2016 |  BC Extra  |  Clinical News

Blueprint, Deciphera present Phase I GIST data

Blueprint Medicines Corp. (NASDAQ:BPMC) and Deciphera Pharmaceuticals LLC (Waltham, Mass.) each presented Phase I data Thursday for candidates targeting stem cell factor (SCF) receptor tyrosine kinase (c-KIT; KIT; CD117) and platelet derived growth factor receptor...
07:00 , Aug 12, 2013 |  BC Week In Review  |  Clinical News

MEDI-575: Development discontinued

AstraZeneca disclosed in its 2Q13 earnings that it discontinued development of MEDI-575 for NSCLC. The pharma cited "safety/efficacy" as the reason for discontinuation. AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K.   Product: MEDI-575   Business: Cancer   Molecular target:...
08:00 , Dec 13, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Neurology Platelet derived growth factor A (PDGFA; PDGF1) A study in mice suggests lithium could help treat...
07:00 , Nov 3, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Diabetes Platelet derived growth factor A (PDGFA; PDGF1); platelet derived growth factor receptor (PDGFR) Mouse and...
07:00 , Nov 3, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Autoimmune disease IL-17C; IL-17 receptor E (IL-17RE) Mouse studies suggest antagonizing IL-17C or its receptor, IL-17RE,...
08:00 , Feb 25, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Brain cancer Poly(ADP-ribose) polymerase-1 (PARP-1); Platelet derived growth factor receptor A (PDGFRA); Platelet derived growth factor A (PDGFA)...